SAN FRANCISCO and SUZHOU, China, May 28, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

Junshi Biosciences has announced that its IL-17 antibody hit the goals of a phase 3 psoriasis trial in China, setting up the biopharma to seek national approval. The Shanghai-headquartered company ...

Scinai Immunotherapeutics Ltd. has released promising preclinical results of its innovative anti‑IL‑17 VHH antibody (NanoAb) as a local treatment for mild to moderate plaque psoriasis.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ensemble Therapeutics, a biotechnology company developing Ensemblins TM, a novel class of small molecule therapeutics with the power of biologics, announced today ...

An experimental Dice Therapeutics drug in development for treating psoriasis now has its first human data showing it reduces the signs and symptoms of the inflammatory skin disorder. The preliminary ...

The results of a Phase 2 study (NCT05970978) showed that switching from other biologics (primarily IL-17 monoclonal antibodies) to picankibart led to a rapid clinical response. The observed efficacy ...